Sarcoma / 2018 / Article / Tab 2

Research Article

Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France

Table 2

Patient characteristics, overall and by country.

CharacteristicOverall ()UK ()Spain ()Germany ()France ()
n%n%n%n%n%

Sex
 Male47558.912663.312360.613063.79647.8
 Female33241.17336.78039.47436.310552.2

Age at advanced diagnosis (years)
 Mean (SD)57.112.356.512.456.613.157.411.057.912.6
 Range (minimum, maximum)21902190218528772284

Ethnicitya
 White/Caucasian56292.717889.520199.018389.7
 African/Black142.3105.00042.0
 Asian or Pacific Islander142.363.00083.9
 Middle eastern81.321.021.042.0
 Indian subcontinent81.331.50052.5

Histologic category
 Leiomyosarcoma22928.46130.74522.26632.45728.4
 Others/NOS18322.74020.13517.24321.16532.3
 Fibroblastic/myofibroblastic sarcoma789.72412.1188.9209.8168.0
 Liposarcoma10513.0147.04421.72210.82512.4
 Vascular sarcoma799.8168.02512.3178.32110.4
 Rhabdomyosarcoma8610.73316.6209.92110.3126.0
 Synovial sarcoma475.8115.5167.9157.452.5

Stage of the disease at initial diagnosis
 1A10.100000010.5
 1B202.563.052.562.931.5
 IIA374.673.594.431.5189.0
 IIB8710.8126.03014.8136.43215.9
 III (with no regional lymph node metastasis)445.563.0104.994.4199.5
 III (with regional lymph node metastasis)617.6115.5104.9167.82411.9
 IV55769.015778.913968.515777.010451.7
 Number of patients where initial diagnosis was not an advanced  stageb18823.32512.65426.62713.28240.8

CCI score at advanced diagnosisc
 Mean (SD)1.01.11.01.11.01.01.01.10.81.2
 Range (minimum, maximum)0605040606

Most common CCI conditions at advanced diagnosisc
 Depression10412.92311.63316.32914.2199.5
 Diabetes without complications10212.62010.14019.73014.7126.0
 Hypertension25932.16432.26331.07436.35828.9

Anatomic location of primary tumor
 Axilla121.552.521.031.521.0
 Breast202.531.573.542.063.0
 Lower extremity18723.24221.15326.15326.03919.4
 Upper extremity9712.02713.62813.82813.7147.0
 Head or neck486.0157.5125.9146.973.5
 Gastrointestinal384.7168.052.5125.952.5
 Genitourinary131.642.031.521.042.0
 Gynecologic (other than uterus)91.110.521.031.531.5
 Mediastinum, lung, or pleura263.242.094.473.463.0
 Pelvis (nonvisceral)658.12311.6136.4178.3126.0
 Retroperitoneal12415.42412.13316.32713.24019.9
 Trunk678.3168.0115.4188.82211.0
 Uterus8510.5136.52210.8167.83416.9
 Unknown131.663.010.50063.0

Site of metastasis among patients with distant metastasis
 Bone10515.92614.43018.12815.62115.6
 Brain162.431.784.821.132.2
 Distant lymph nodes16124.45631.13621.75128.31813.3
 Exoskeletal284.2105.663.695.032.2
 Liver18728.35832.24225.35631.13123.0
 Lung46870.811262.212575.312569.410678.5
 Mediastinum385.8116.1116.684.485.9
 Pericardium91.421.131.831.710.7
 Peritoneum9814.83217.8159.03016.72115.6
 Pleura426.484.4127.295.0139.6
 Retroperitoneum182.752.853.052.832.2
 Others50.810.6000043.0
 Unknown20.310.610.60000

ECOG PS at advanced diagnosis
 PS 08410.4157.52311.3188.82813.9
 PS 147458.716281.48642.414470.68240.8
 PS ≥ 224930.92211.19446.34220.69145.3

CCI: Charlson Comorbidity Index; ECOG: Eastern Cooperative Oncology Group; NOS: not otherwise specified; PS: performance status; SD: standard deviation; STS: soft tissue sarcoma; UK: United Kingdom; anot collected in France; bpatients with stage I, II, or III at initial diagnosis and with time from initial to advanced diagnosis greater than zero; cbecause the objective of the CCI score was to evaluate underlying comorbidity burden independent of STS, cancer was excluded from the CCI calculation for this study.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.